🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Intellia Therapeutics Inc (NTLA)

NASDAQ
Currency in USD
16.73
+0.73(+4.56%)
Closed
After Hours
16.730.00(0.00%)
NTLA Scorecard
Full Analysis
6 analysts have revised their earnings upwards for the upcoming period
Fair Value
Day's Range
15.6117.00
52 wk Range
13.9534.87
Prev. Close
16
Open
16.05
Day's Range
15.61-17
52 wk Range
13.95-34.87
Volume
2,418,301
Average Volume (3m)
1,892,440
1-Year Change
-32.97%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
NTLA Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
62.78
Upside
+275.25%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Intellia Therapeutics Inc Company Profile

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

InvestingPro Research for Intellia Therapeutics Inc


Gene Editing Pionee
Intellia Therapeutics leads in CRISPR/Cas9 technology, with promising clinical trials for hereditary angioedema and transthyretin amyloidosis treatments
Financial Outlook
Strong $953M cash position supports operations into late 2026, despite current losses. Analyst price targets range from $54 to $76 per share
Market Potential
Explore Intellia's position in multi-billion dollar markets for HAE and ATTR, with potential to revolutionize treatment through one-time gene editing therapies
Challenges Ahead
Delve into regulatory hurdles, competition, and public perception issues facing Intellia as it navigates the complex landscape of gene editing technologies
Read full SWOT analysis

Compare NTLA to Peers and Sector

Metrics to compare
NTLA
Peers
Sector
Relationship
P/E Ratio
−3.3x−3.6x−0.6x
PEG Ratio
1.830.000.00
Price/Book
1.8x3.9x2.6x
Price / LTM Sales
39.4x20.4x3.2x
Upside (Analyst Target)
262.0%209.4%44.1%
Fair Value Upside
Unlock9.6%6.2%Unlock

People Also Watch

8.90
VRM
-3.16%
231.64
BDX
+1.99%
2.300
PACB
-6.12%
23.65
CDNA
-0.96%
19.89
PD
-1.78%

FAQ

What Is the Intellia Therapeutics Inc (NTLA) Stock Price Today?

The Intellia Therapeutics Inc stock price today is 16.73

What Stock Exchange Does Intellia Therapeutics Inc Trade On?

Intellia Therapeutics Inc is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Intellia Therapeutics Inc?

The stock symbol for Intellia Therapeutics Inc is "NTLA."

What Is the Intellia Therapeutics Inc Market Cap?

As of today, Intellia Therapeutics Inc market cap is 1.70B.

What is Intellia Therapeutics Inc Earnings Per Share?

The Intellia Therapeutics Inc EPS is -5.44.

What Is the Next Intellia Therapeutics Inc Earnings Date?

Intellia Therapeutics Inc will release its next earnings report on Feb 20, 2025.

From a Technical Analysis Perspective, Is NTLA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.